Skip to main content

Researcher Roger Gomis receives a grant from the Fundación Fero to study metastatic breast cancer

Images

Participants

Contact

Image
Press & Communications Section Head
Tel.+34 93 40 37255

The funded project will address the development of metastasis in breast cancer. 

The grant, which is specifically for research into breast cancer, has been given by the foundation, in collaboration with Mango.

Fero is a private foundation that promotes translational cancer research in Spain.

The Fundación Fero, an organisation devoted to furthering cancer research, with the collaboration of Mango, has awarded ICREA researcher Roger Gomis, head of the Growth Control and Metastasis Laboratory at the Institute for Research in Biomedicine (IRB Barcelona), funding for his project “Identification of the pro-metastatic properties of the fibroblasts derived from MSCs in luminal breast cancer”.

For the 17th Fero Grants in Translational Cancer Research, the foundation has awarded two €80,000-grants, one of which has been given to Gomis’ project, which addresses the development of breast cancer metastasis

The grants were presented last night in one of two yearly charity events organised by the foundation in Madrid and, once again, under the auspices of Andbank.

 

Study of the development of breast cancer metastasis

The research headed by Gomis focuses on luminal breast cancer—one of the most common subtypes of breast cancer—in which metastasis occurs mainly to the bone. This kind of cancer can cause metastasis after many years of remission and can lead to rapid death. 

“In recent years, it has been observed that tumour cells that cause metastasis in this kind of cancer possibly interact with fibroblasts derived from MSCs in the bone. These interactions have effects on the tumour, and they may underlie metastasis relapse and condition the response to systemic therapies,” said the scientist. 

“Our project aims to unravel these interactions, to identify therapeutic targets and to limit the capacity of these cells to cause metastasis,” explained Gomis.

 

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).